Clinical Trials
3 trialsNCT02768766 2023-08-31
Intermittent Selumetinib for Uveal Melanoma
Columbia University
Phase 1 Completed
NCT01143402 2017-07-26
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT01974752 2017-01-05
SUMIT
AstraZeneca
Phase 3 Completed